ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study for the Treatment of Cystic Fibrosis
ReCode Therapeutics, a clinical-stage genetic medicines company, announced the dosing of the first patient in a Phase 1b study of RCT2100, an investigational inhaled mRNA therapy for cystic fibrosis (CF). CF, caused by mutations in the CFTR gene, affects around 130,000 people worldwide. While CFTR modulator therapies have improved outcomes for many, those with certain mutations still lack effective treatments. RCT2100 aims to address this by delivering CFTR mRNA directly to lung cells, potentially restoring CFTR protein function and tackling the root cause of CF. “The initiation of our Phase 1b study of RCT2100 in cystic fibrosis marks a significant milestone for us and is a step closer to offering new hope to those who cannot benefit from existing CF therapies,” said ReCode CEO, Dr. Shehnaaz Suliman.
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study for the Treatment of Cystic Fibrosis